The compound moved through Phase I trials, which primarily assess safety in humans, and appeared to have a very favorable safety profile
In 2023, both were placed on a list of substances considered high-risk for compounding
I felt terrible, and for a few days after my balance, speach and memory were all affected
Designed solely for parenteral use (drug administration by intravenous, intramuscular, or subcutaneous injection) following the addition of drugs that require dilution or must be dissolved in an aqueous vehicle prior to injecting
Tesofensine exhibits nanomolar affinity for dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT), providing a broad multi-transporter interaction profile